# A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

> **NCT02453256** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 212 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02453256
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-20
- **Primary completion:** 2018-01-15
- **Final completion:** 2019-02-04
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2020-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02453256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02453256, "A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02453256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*